<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02775448</url>
  </required_header>
  <id_info>
    <org_study_id>HospitalNHMexico</org_study_id>
    <nct_id>NCT02775448</nct_id>
  </id_info>
  <brief_title>Dose-response Study of Carduus Marianus in Centesimal Scale for Dyslipidemia in Climacteric Overweighed or Obese Women.</brief_title>
  <official_title>Dose-response Study of the Efficacy and Safety of Carduus Marianus in Centesimal Scale for Dyslipidemia in Overweighed or Obese Women in Peri- and Postmenopause: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Nacional Homeopático, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorio Similia, México</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Nacional Homeopático, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic disorders including hypercholesterolemia and hypertriglyceridemia are present in
      climacteric women. Carduus marianus is a homeopathic medicine that traditionally has been
      used for hepatic diseases. It has been used for reducing hypercholesterolemia and
      hypertriglyceridemia also. The aim of this study is to investigate the most effective dose of
      Carduus marianus in centesimal scale (6cH, 12cH, 30cH, placebo) plus diet and exercise for
      reducing hypertriglyceridemia and/or hypercholesterolemia in climacteric women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of metabolic disorders including dyslipidemia increases as women transition
      from premenopause to postmenopause. This increases the risk for morbidity and mortality from
      cardiovascular diseases. Carduus marianus is a homeopathic medicine that traditionally has
      been used for hepatic diseases. Silymarin, isolated from Carduus marianus, owe its
      therapeutic and hepatoprotective effects to its strong antioxidant and anti-inflammatory
      properties. Carduus marianus is frequently used in clinical practice and reduces plasma level
      of triglycerides, total cholesterol and LDL in humans with dyslipidemia. Not all homeopaths
      agree on dosage and potency when prescribing homeopathic medicines. The aim of this study is
      to assess: (1) the most effective dose of Carduus marianus in centesimal scale for reducing
      hypertriglyceridemia and/or hypercholesterolemia in climacteric women; (2) the effect of
      Carduus marianus in other metabolic parameters (glucose, glycosylated hemoglobin, insulin
      resistance, weight, body mass index, waist circumference).

      This is a 8-week, double-blind, randomized, parallel, four-group, dose-response study to
      assess the safety and efficacy of Carduus marianus in 6cH, 12cH, 30cH and placebo plus diet
      and exercise, for reducing hypertriglyceridemia and/or hypercholesterolemia in climacteric
      women.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline level of triglycerides at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline level of total cholesterol at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline level of LDL cholesterol at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline level of HDL cholesterol at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline level of fasting glucose at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline level of glycosylated hemoglobin at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline [HOMA-IR=insulin(mU/ml) X glucose (mg/dl)/405] at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline weight (kg) at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline body mass index (Kg/m2) at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline waist circumference (cm) at 4 and 8 weeks.</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 weeks after randomization</time_frame>
    <description>Untoward medical occurrence associated with the use of a drugs in humans, whether or not considered drug related.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks after randomization</time_frame>
    <description>Untoward medical occurrence associated with the use of a drugs in humans, whether or not considered drug related.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Menopause</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Diet + exercise + Carduus marianus 6cH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet + exercise + Carduus marianus 12cH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet + exercise + Carduus marianus 30cH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet + exercise + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carduus marianus 6cH</intervention_name>
    <arm_group_label>Diet + exercise + Carduus marianus 6cH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carduus marianus 12cH</intervention_name>
    <arm_group_label>Diet + exercise + Carduus marianus 12cH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carduus marianus 30cH</intervention_name>
    <arm_group_label>Diet + exercise + Carduus marianus 30cH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Diet + exercise + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>aerobic exercise, 30 minutes, daily</description>
    <arm_group_label>Diet + exercise + Carduus marianus 6cH</arm_group_label>
    <arm_group_label>Diet + exercise + Carduus marianus 12cH</arm_group_label>
    <arm_group_label>Diet + exercise + Carduus marianus 30cH</arm_group_label>
    <arm_group_label>Diet + exercise + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>1600 calories</description>
    <arm_group_label>Diet + exercise + Carduus marianus 6cH</arm_group_label>
    <arm_group_label>Diet + exercise + Carduus marianus 12cH</arm_group_label>
    <arm_group_label>Diet + exercise + Carduus marianus 30cH</arm_group_label>
    <arm_group_label>Diet + exercise + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women 40-65 years in early or late transition to menopause or postmenopause according
             to STRAW classification

          2. hypertriglyceridemia [&gt;150 &lt;1000 mg/dL], and/or hypercholesterolemia [&gt;200mg/dL]

          3. overweight or obesity [BMI &gt;25 Kg/m2]

          4. fasting glucose &lt;126mg/dL

          5. glycosylated hemoglobin &lt;6.5%

          6. be willing and capable to follow study procedures.

        Exclusion Criteria:

          1. history of cardiovascular disease or coronary risk equivalents

          2. secondary hyperlipidemia caused by diabetes mellitus, renal, liver or thyroid diseases

          3. hypolipidemic agents, antidiabetic medication, hormone replacement therapy, tamoxifen,
             raloxifene, danazol, isotretinoin, acitretin, cyclosporin, azathioprine, protease
             inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), antipsychotics
             (clozapine), seizure medication (carbamazepine, valproic acid, phenobarbital,
             phenytoin) either on-going or any time in the previous 2 months

          4. any other clinically significant illness that, in the opinion of the investigator,
             might put the patient at risk of harm during the study or might adversely affect the
             interpretation of the study data

          5. pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma del Carmen Macias-Cortes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nacional Homeopático</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma del Carmen Macías-Cortés, PhD</last_name>
    <phone>+5215519165947</phone>
    <email>ecmc2008@hotmail.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gloria Hernández-Ruiz, MD</last_name>
    <phone>+5215591958511</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Nacional Homeopático</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma del Carmen Macias-Cortes, PhD</last_name>
      <phone>15519165947</phone>
      <email>ecmc2008@hotmail.es</email>
    </contact>
    <contact_backup>
      <last_name>Gloria Hernández-Ruiz, MD</last_name>
      <phone>+5215591958511</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2016</study_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Nacional Homeopático, Mexico</investigator_affiliation>
    <investigator_full_name>Emma del Carmen Macías-Cortés, PhD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Homeopathy</keyword>
  <keyword>Carduus marianus</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Climacteric</keyword>
  <keyword>Obesity</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>LDL-cholesterol</keyword>
  <keyword>HDL-cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

